•  
  •  
 
The University of Louisville Journal of Respiratory Infections

Abstract

A 72-year-old male presented to the emergency department with a chief complaint of diarrhea after having tested positive for COVID-19 two days prior. He initially had minimal respiratory complaints, but was eventually transferred to the intensive care unit for acute hypoxic respiratory failure. In addition to dexamethasone, remdesivir, and antibiotics, the patient was treated with baricitinib, a Janus kinase inhibitor that was recently granted emergency use authorization by the Food and Drug Administration for treatment of hospitalized patients with COVID-19. He had an extensive and complicated hospital course and had to be placed on mechanical ventilation, ultimately undergoing tracheostomy. After 78 days of hospitalization, his family withdrew life-sustaining measures and the patient died shortly thereafter. This case details the use of baricitinib for treatment of COVID-19 pneumonia, and demonstrates the need for additional studies regarding the efficacy of this drug.

Funder

The author(s) received no specific funding for this work.

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

1200figure1a.jpg (27 kB)
Hospital day 1: Patchy right infrahilar opacities concerning for pneumonia and/or atelectasis

1200figure1b.jpg (31 kB)
Hospital day 4: Interval worsening of the bilateral patchy airspace opacities

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.